Reduced endogenous insulin secretion in diabetic patients with low-titer positive antibodies against GAD

Yuichiro Takeuchi, Hiroyuki Ito, Koshiro Oshikiri, Shinichi Antoku, Mariko Abe, Mizuo Mifune, Michiko Togane, Masahiro Kato

.
Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Tokyo, Japan;.

DOI: 10.4236/jdm.2012.21015                

Abstract

Aim: To investigate the clinical characteristics of diabetic patients with a low-titer positive for the anti-glutamic acid decarboxylase 65 antibody (GAD antibody). Methods: The subjects were 420 diabetic inpatients. The endogenous insulin secretion was estimated on the basis of the C-peptide immunoreactivity from a 24 h urine collection (uCPR). Clinical variables were compared between patients negative for the GAD antibody (GAD antibody titer < 1.5 U/mL), a low-titer positive GAD antibody (1.5 U/mL ≤ GAD antibody titer < 10 U/mL) and a high-titer positive GAD antibody (10 U/mL ≤ GAD antibody titer). Results: The low and high-titer positive GAD antibodies were found in 25 and 10 patients, respectively. The uCPR was significantly lower in both the patients with a low (37 ± 33 ug/24h) and high-titer (39 ± 27 ug/24h) positive GAD antibodies than in those negative for GAD antibodies (71 ± 52 ug/24h). The uCPR level was significantly lower in the low-titer positive GAD antibody group (29 ± 22 ug/24h) than in the negative group (67 ± 55 ug/24h) among the patients not taking insulin secretagogues. The difference disappeared in the subjects taking insulin secreagogues. In the stepwise multiple regression analysis, a low-titer positive GAD antibody was independently associated with the uCPR level. Conclusions: Endogenous insulin secretion is reduced in diabetic patients positive for GAD antibodies, even if the titer is low. Earlier initiation of insulin therapy might therefore protect the pancreatic β-cell function in diabetic patients with a low-titer positive GAD antibody.

Keywords

GAD Antibody; Endogenous Insulin Secretion; Urinary C-Peptide; SPIDDM; LADA

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Baekkeskov, S., Aanstoot, H.J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H. and De Camilli, P. (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature, 347, 151-156. doi:10.1038/347151a0
[2]	Tuomi, T., Groop, L.C., Zimmet, P.Z., Rowley, M.J., Knowles, W. and Mackay, I.R. (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes, 42, 359-362. doi:10.2337/diabetes.42.2.359
[3]	Hagopian, W.A., Karlsen, A.E., Gottsater, A., Landin-Olsson, M., Grubin, C.E., Sundkvist, G., Petersen, J.S., Boel, E., Dyrberg, T. and Lernmark, A. (1993) Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. The Journal of Clinical Investigation, 91, 368-374. doi:10.1172/JCI116195
[4]	Turner, R., Stratton, I., Horton, V., Manley, S., Zimmet, P., Mackay, I.R., Shattock, M., Bottazzo, G.F. and Holman, R. (1997) UKPDS 25: Autoantibodies to islet cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet, 350, 1288-1293. doi:10.1016/S0140-6736(97)03062-6
[5]	Gottsatter, A., Landin-Olsson, M., Lernmark, A., Fernlund, P., Sundkvist, G. and Hapopian, W.A. (1995) Glutamic decarboxylase antibody level predicts rate of B-cell declining in adult-onset diabetes. Diabetes Research and Clinical Practice, 27, 133-140. doi:10.1016/0168-8227(95)01026-A
[6]	Willis, J.A., Scot, R.S. and Brown, L.J. (1996) Islet cell antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Research and Clinical Practice, 33, 89-97. doi:10.1016/0168-8227(96)01281-8
[7]	Buzzetti, R., Di Pietro, S., Giaccari, A., Petrone, A., Locatelli, M., Suraci, C., Capizzi, M., Arpi, M.L., Bazzigaluppi, E., Dotta, F., Bosi, E. and Non Insulin Requiring Autoimmune Diabetes Study Group (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care, 30, 932-938. doi:10.2337/dc06-1696
[8]	De Block, C.E., De Leeuw, I.H., Vertommen, J.J., Rooman, R.P., Du Caju, M.V., Van Campenhout, C.M., Weyler, J.J., Winnock, F., Van Autreve, J., Gorus, F.K. and Belgian Diabetes Registry (2001) Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clinical and Experimental Immunology, 126, 236-241. doi:10.1046/j.1365-2249.2001.01668.x
[9]	Barova, H., Perusicova, J., Hill, M., Sterzl, I., Vondra, K. and Masek, Z. (2004) Anti-GAD-positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiological Research, 53, 279-286.
[10]	Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., Kasuga, M., Hanafusa, T. and Haneda, M. (2010) Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 1, 213-228.
[11]	Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H. and Hishida, A. (2009) Revised equations for estimated GFR from serum creatinine in Japan. American Journal of Kidney Diseases, 53, 982-992. doi:10.1053/j.ajkd.2008.12.034
[12]	Coresh, J., Astor, B.C., Greene, T., Eknoyan, G. and Levey, A.S. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. American Journal of Kidney Diseases, 41, 1-12. doi:10.1053/ajkd.2003.50007
[13]	Ohta, M., Obayashi, H., Takahashi, K., Kitagawa, Y., Nakano, K., Matsuo, S., Nishimura, M., Itoh, N. and Ohta, K. (1996) Radioimmunoprecipitation assay for glutamic acid decarboxylase antibodies evaluated clinically with sera from patients with insulin-dependent diabetes mellitus. Clinical Chemistry, 42, 1975-1978.
[14]	Fukui, M., Nakano, K., Shigeta, H., Yoshimori, K., Fujii, M., Kitagawa, Y., Mori, H., Kajiyama, S., Nakamura, N., Abe, N., Obayashi, H., Fukui, I., Ohta, K., Ohta, M. and Kondo, M. (1997) Antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary failure of oral hypoglycaemic therapy. Diabetic Medicine, 14, 148-152. doi:10.1002/(SICI)1096-9136(199702)14:2<148::AID-DIA317>3.0.CO;2-9
[15]	Fukui, M., Nakamura, N., Nakano, K., Sawada, M., Aoji, O., Obayashi, H., Shigeta, H. and Kondo, M. (1998) Antibodies to GAD in elderly patients with previously diagnosed NIDDM. Diabetes Care, 21, 675-676. doi:10.2337/diacare.21.4.675
[16]	Kasuga, A., Maruyama, T., Nakamoto, S., Ozawa, Y., Suzuki, Y. and Saruta, T. (1999) High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. Journal of Autoimmunity, 12, 131-135. doi:10.1006/jaut.1998.0261
[17]	Kulmala, P., Savola, K., Petersen, J.S., Vahasalo, P., Karjalainen, J., Lopponen, T., Dyrberg, T., Akerblom, H.K. and Knip, M. (1998) Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. The Journal of Clinical Investigation, 101, 327-333. doi:10.1172/JCI119879
[18]	Tuomi, T., Carlsson, A., Li, H., Isomaa, B., Miettinen, A., Nilsson, A., Nissen, M., Ehrnstrom, B.O., Forsen, B., Snickars, B., Lahti, K., Forsblom, C., Saloranta, C., Taskinen, M.R. and Groop, L.C. (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes, 48, 150-157. doi:10.2337/diabetes.48.1.150
[19]	Maruyama, T., Tanaka, S., Shimada, A., Funae, O., Kasuga, A., Kanatsuka, A., Takei, I., Yamada, S., Harii, N., Shimura, H. and Kobayashi, T. (2008) Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism, 93, 2115-2121. doi:10.1210/jc.2007-2267